The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Guillermo Garcia-Manero, MD, spotlights the evolution of oral azacitidine- and decitabine-based regimens for MDS.

A panel of expert hematologic-oncologists offer insights on how they treat patients with multiple myeloma at early relapse.

The expert panel discusses how the standard of care for transplant-ineligible NDMM has evolved and reviews recent updates in this space.

Adjuvant chemotherapy did not improve circulating tumor DNA clearance in patients with stage II colon cancer with baseline circulating tumor DNA.

Amrita Krishnan, MD, and Saad Z. Usmani, MD, MBA, FACP, offer their perspectives on the role of stem cell transplant and MRD testing in patients with newly diagnosed multiple myeloma.

Clinical insights on the definition of high-risk multiple myeloma and the treatment of patients with high risk disease, including how the results from the IsKia trial might impact practice.

Experts in multiple myeloma discuss highlights from the ASH 2023 meeting around transplant-eligible NDMM with particular focus on the PERSEUS and GRIFFIN trials and the clinical implications of the results of these studies.

Neil D. Gross, MD, FACS, shares how neoadjuvant cemiplimab followed by surgery improved EFS in patients with stage II-IV cutaneous squamous cell carcinoma.

Alessandra Ferrajoli, MD, discusses the research needs for describing the risk of hypertension linked with BTK inhibitors in chronic lymphocytic leukemia.

Hans C. Lee, MD, discusses updated data from the phase 2 LINKER-MM1 study evaluating linvoseltamab in patients with relapsed/refractory multiple myeloma.

Eric Jonasch, MD, discusses the goals of a meeting sponsored by the International Kidney Cancer Coalition that will focus on patient advocacy in GU malignancies.

Alessandra Ferrajoli, MD, discusses the rationale for, and findings from, a cumulative review of hypertension in patients with chronic lymphocytic leukemia and other hematologic malignancies who received acalabrutinib.

The pain and suffering that Eduardo Bruera, MD, FAAHPM, witnessed in patients during his clinical oncology rotations motivated him to reshape palliative care treatment.

Fernando Cabanillas, MD, a mentor and leader in the lymphoma field, is being recognized for his contributions to the hematologic oncology space.

In case you missed it, here is a recap of the most popular episodes of OncLive On Air® from 2023.

Dr Jabbour discusses the activity and the utilization of olverembatinib in chronic myeloid leukemia and expanded upon the role that TKIs can play in the management of malignancies beyond chronic myeloid leukemia and acute lymphoblastic leukemia.

The presence of ESR1 coabnormalities, including TP53 and PIK3CA mutations, and CCND1 and FGFR1 amplification, did not demonstrate a negative impact on the efficacy with lasofoxifene and abemaciclib in patients with estrogen receptor–positive, ESR1-mutant metastatic breast cancer.

Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development.

Guillermo Garcia-Manero, MD, presents data from the COMMANDS trial investigating luspatercept in erythropoiesis-stimulating agent-naive patients with transfusion-dependent lower-risk myelodysplastic syndromes.

Leading experts discuss the exciting progress and challenges in the field of kidney cancer treatment, addressing topics like immunotherapy, biomarkers, and the role of multidisciplinary care.

Experts discuss the potential of triple combination therapies for high-risk renal cell carcinoma (RCC) patients and the challenges posed by their toxicity profiles, emphasizing the need for compelling clinical trial data.

Treatment with SD-101 distributed via pressure-enabled drug delivery with immune checkpoint inhibition was tolerated and resulted in the depletion of Tregs, M-MDSCs, and M2 macrophages in liver metastases in patients with uveal melanoma.

A panel of experts discuss the evolving landscape of newly diagnosed multiple myeloma.

Leading oncologists discuss advanced treatment options for patients with progressing renal cell carcinoma (RCC), focusing on the promising results from LITESPARK-005 and treatment sequencing strategies.

Expert insight into how to discuss and manage treatment-related toxicities with cancer patients and their families, emphasizing the importance of early communication and vigilance.

The high-precision cellular product Orca-Q demonstrated early signals of clinical activity as well as an acceptable safety profile for patients undergoing haploidentical stem cell transplantation without posttransplant cyclophosphamide.

Brentuximab vedotin plus nivolumab, doxorubicin, and dacarbazine was found to have efficacy and acceptable safety and tolerability when used as a frontline treatment in patients with previously untreated advanced, classical Hodgkin lymphoma.

Up-front treatment with navitoclax plus ruxolitinib significantly reduced spleen volume by 35% or more at week 24 vs ruxolitinib plus placebo in patients with myelofibrosis; however, a significant difference was not observed in total symptom score v. 4.0 between the arms, according to data from the phase 3 TRANSFORM-1 study.

Revumenib, decitabine/cedazuridine, plus venetoclax elicited an objective response rate of 100% with acceptable safety in patients with relapsed/refractory acute myeloid leukemia enrolled in the small phase 1/2 SAVE study.

Senthil Damodaran, MD, PhD, discusses the efficacy of futibatinib plus fulvestrant in patients with FGFR1-amplified metastatic hormone receptor–positive, HER2-negative breast cancer according to findings from the phase 2 FOENIX-MBC2 trial.